Pharvaris Presents Data at the Bradykinin Symposium 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Pharvaris B.V. (PHVS) PT Raised to $42 at Oppenheimer
September 6, 2024 5:07 AM EDTOppenheimer analyst Justin Kim raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $42.00 (from $38.00) while maintaining a Outperform rating.
The analyst comments "On Thursday PHVS presented 2 oral presentations and 10 posters at the bradykinin symposium focused on HAE. Critical to the PHVS... More
